Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,519.15
(
-1.10%
)
US TECH 100
23,166.00
(
-1.47%
)
Dow Jones
46,091.20
(
-0.73%
)
Brent Oil
102.59
(
3.86%
)
Bitcoin
68,868.19
(
-3.42%
)
News Focus
News Focus
Post# of 257293
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122813
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 6274

Thursday, 12/30/2004 6:58:02 PM

Thursday, December 30, 2004 6:58:02 PM

Post# of 257293
That was an amusing AIDS blurb. Now fast-forward 13 years to the 2003 acquisition of ISI by HEB:

“…We believe that Hemispherx has a unique broad based experimental platform of immune based therapies that shows substantial potential to benefit the scientific community regarding HIV/AIDS, CFS, hepatitis, bioterror, multiple sclerosis, cancer and various sexually transmitted viral infections."

http://www.biospace.com/news_story.cfm?StoryID=11978220&full=1

No discussion required.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up